GLAUKOS CORP (GKOS) Stock Fundamental Analysis
USA - NYSE:GKOS - US3773221029 - Common Stock
88.07 USD
+0.27 (+0.31%)
88.07 USD
0 (0%)
Overall GKOS gets a fundamental rating of 4 out of 10. We evaluated GKOS against 189 industry peers in the Health Care Equipment & Supplies industry. While GKOS seems to be doing ok healthwise, there are quite some concerns on its profitability. GKOS shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
In the past year GKOS has reported negative net income.
In the past year GKOS has reported a negative cash flow from operations.
GKOS had negative earnings in each of the past 5 years.
GKOS had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
The Return On Assets of GKOS (-9.40%) is better than 62.43% of its industry peers.
With a decent Return On Equity value of -12.13%, GKOS is doing good in the industry, outperforming 64.55% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -9.4% | ||
| ROE | -12.13% | ||
| ROIC | N/A |
ROA(3y)-13.08%
ROA(5y)-11.18%
ROE(3y)-22.32%
ROE(5y)-18.69%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 76.34%, GKOS belongs to the top of the industry, outperforming 88.36% of the companies in the same industry.
In the last couple of years the Gross Margin of GKOS has declined.
The Profit Margin and Operating Margin are not available for GKOS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 76.34% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.81%
GM growth 5Y-2.05%
2. Health
2.1 Basic Checks
GKOS does not have a ROIC to compare to the WACC, probably because it is not profitable.
GKOS has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, GKOS has more shares outstanding
The debt/assets ratio for GKOS has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 13.06 indicates that GKOS is not in any danger for bankruptcy at the moment.
GKOS's Altman-Z score of 13.06 is amongst the best of the industry. GKOS outperforms 93.12% of its industry peers.
A Debt/Equity ratio of 0.09 indicates that GKOS is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.09, GKOS is in the better half of the industry, outperforming 65.61% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 13.06 |
ROIC/WACCN/A
WACC8.47%
2.3 Liquidity
A Current Ratio of 5.51 indicates that GKOS has no problem at all paying its short term obligations.
GKOS has a better Current ratio (5.51) than 80.95% of its industry peers.
GKOS has a Quick Ratio of 4.69. This indicates that GKOS is financially healthy and has no problem in meeting its short term obligations.
GKOS has a Quick ratio of 4.69. This is amongst the best in the industry. GKOS outperforms 81.48% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.51 | ||
| Quick Ratio | 4.69 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 52.11% over the past year.
Looking at the last year, GKOS shows a very strong growth in Revenue. The Revenue has grown by 21.85%.
The Revenue has been growing by 10.10% on average over the past years. This is quite good.
EPS 1Y (TTM)52.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.86%
Revenue 1Y (TTM)21.85%
Revenue growth 3Y9.26%
Revenue growth 5Y10.1%
Sales Q2Q%38.14%
3.2 Future
The Earnings Per Share is expected to grow by 29.04% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 26.93% on average over the next years. This is a very strong growth
EPS Next Y51.88%
EPS Next 2Y40.35%
EPS Next 3Y34.31%
EPS Next 5Y29.04%
Revenue Next Year27.96%
Revenue Next 2Y26.71%
Revenue Next 3Y26.32%
Revenue Next 5Y26.93%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
GKOS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GKOS. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as GKOS's earnings are expected to grow with 34.31% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.35%
EPS Next 3Y34.31%
5. Dividend
5.1 Amount
No dividends for GKOS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
88.07
+0.27 (+0.31%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners107.33%
Inst Owner Change0.18%
Ins Owners3.31%
Ins Owner Change0.63%
Market Cap5.05B
Revenue(TTM)383.48M
Net Income(TTM)-92792000
Analysts82.73
Price Target120.44 (36.75%)
Short Float %4.34%
Short Ratio2.73
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)24.51%
Min EPS beat(2)11.08%
Max EPS beat(2)37.95%
EPS beat(4)3
Avg EPS beat(4)22.32%
Min EPS beat(4)-2.27%
Max EPS beat(4)42.53%
EPS beat(8)5
Avg EPS beat(8)8.64%
EPS beat(12)8
Avg EPS beat(12)7.63%
EPS beat(16)11
Avg EPS beat(16)4.11%
Revenue beat(2)2
Avg Revenue beat(2)3.68%
Min Revenue beat(2)2.01%
Max Revenue beat(2)5.35%
Revenue beat(4)4
Avg Revenue beat(4)3.41%
Min Revenue beat(4)2.01%
Max Revenue beat(4)5.35%
Revenue beat(8)8
Avg Revenue beat(8)3.55%
Revenue beat(12)12
Avg Revenue beat(12)3.87%
Revenue beat(16)16
Avg Revenue beat(16)4.23%
PT rev (1m)-0.4%
PT rev (3m)-1.07%
EPS NQ rev (1m)0.46%
EPS NQ rev (3m)-11.96%
EPS NY rev (1m)-0.25%
EPS NY rev (3m)-6.49%
Revenue NQ rev (1m)0.03%
Revenue NQ rev (3m)1.72%
Revenue NY rev (1m)0.05%
Revenue NY rev (3m)0.8%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 11.67 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 6.6 | ||
| P/tB | 11.8 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.02
EYN/A
EPS(NY)-0.06
Fwd EYN/A
FCF(TTM)-0.76
FCFYN/A
OCF(TTM)-0.36
OCFYN/A
SpS7.55
BVpS13.34
TBVpS7.46
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -9.4% | ||
| ROE | -12.13% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 76.34% | ||
| FCFM | N/A |
ROA(3y)-13.08%
ROA(5y)-11.18%
ROE(3y)-22.32%
ROE(5y)-18.69%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.81%
GM growth 5Y-2.05%
F-Score5
Asset Turnover0.44
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 55.95% | ||
| Cap/Sales | 5.29% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.51 | ||
| Quick Ratio | 4.69 | ||
| Altman-Z | 13.06 |
F-Score5
WACC8.47%
ROIC/WACCN/A
Cap/Depr(3y)54.99%
Cap/Depr(5y)69.95%
Cap/Sales(3y)6.26%
Cap/Sales(5y)7.62%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.86%
EPS Next Y51.88%
EPS Next 2Y40.35%
EPS Next 3Y34.31%
EPS Next 5Y29.04%
Revenue 1Y (TTM)21.85%
Revenue growth 3Y9.26%
Revenue growth 5Y10.1%
Sales Q2Q%38.14%
Revenue Next Year27.96%
Revenue Next 2Y26.71%
Revenue Next 3Y26.32%
Revenue Next 5Y26.93%
EBIT growth 1Y19.05%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year59.19%
EBIT Next 3Y45.08%
EBIT Next 5Y43.81%
FCF growth 1Y54.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y70.36%
OCF growth 3YN/A
OCF growth 5YN/A
GLAUKOS CORP / GKOS FAQ
Can you provide the ChartMill fundamental rating for GLAUKOS CORP?
ChartMill assigns a fundamental rating of 4 / 10 to GKOS.
What is the valuation status of GLAUKOS CORP (GKOS) stock?
ChartMill assigns a valuation rating of 1 / 10 to GLAUKOS CORP (GKOS). This can be considered as Overvalued.
How profitable is GLAUKOS CORP (GKOS) stock?
GLAUKOS CORP (GKOS) has a profitability rating of 2 / 10.
Can you provide the financial health for GKOS stock?
The financial health rating of GLAUKOS CORP (GKOS) is 6 / 10.
Can you provide the expected EPS growth for GKOS stock?
The Earnings per Share (EPS) of GLAUKOS CORP (GKOS) is expected to grow by 51.88% in the next year.